Core Viewpoint - Jiangzhong Pharmaceutical (600750) announced the acquisition of 70% equity in Anhui Jingcheng Huyao Pharmaceutical Co., Ltd. for a price not exceeding 70.78393 million yuan, aiming to enhance its OTC product matrix with traditional Chinese medicine products [1] Group 1: Acquisition Details - The acquisition will allow Jiangzhong Pharmaceutical to supplement its product offerings in the traditional Chinese medicine sector, particularly in the health supplement category [1] - Anhui Jingcheng Huyao, established in November 2013 with a registered capital of 51 million yuan, focuses on the R&D, production, and sales of traditional Chinese medicine [1] - The core products of Jingcheng Huyao include Liuwei Dihuang Oral Liquid, Nao Li Jing Syrup, and Nao Li Jing Capsules [1] Group 2: Company Background - Jingcheng Huyao was previously known as Bengbu Traditional Chinese Medicine Factory, founded in 1968, and was fully acquired by Peitian Group in 2015 [1] - The company was listed on the Specialized and New Board of Anhui Stock Custody Center in October 2021 [1] Group 3: Operational Challenges - Peitian Group, the current owner of Jingcheng Huyao, has faced operational difficulties due to poor management, market changes, and heavy debt burdens, leading to a debt crisis in 2018 [3] - The company underwent a restructuring process initiated by the government and asset management companies to address its financial issues [3] - As part of the restructuring plan, the court approved a merger and restructuring plan for Peitian Group and its subsidiaries, including Jingcheng Huyao, in September 2024 [3]

每经AI快讯，江中药业（SH 600750，收盘价：21.8元）9月26日晚间发布公告称，公司第十届第八次董 事会会议于2025年9月25日在公司会议室以现场结合视频方式召开。会议审议了《关于对外转让桑海制 药51.0044%股权的议案》等文件。 2025年1至6月份，江中药业的营业收入构成为：医药工业占比99.64%，酒业占比0.25%，其他业务占比 0.11%。 （记者 曾健辉） 截至发稿，江中药业市值为138亿元。 每经头条（nbdtoutiao）——5年增长33倍，这类新险种卖爆了，身边很多人都需要，30多家险企蜂拥而 入⋯⋯ ...

证券代码：600750 证券简称：江中药业 公告编号：2025-049 江中药业股份有限公司 一、关于拟收购精诚徽药 70%股权的议案 表决情况：9 票同意，0 票反对，0 票弃权，通过本议案。 为补充中药补益类品种、丰富 OTC 产品矩阵，同意公司作为意向受让方以 自有资金通过公开摘牌方式收购安徽省精诚徽药药业有限公司（以下简称"精 诚徽药"）70%股权。精诚徽药主要从事中成药的研发、生产和销售，聚焦中药 补益类 OTC 产品，核心品种为六味地黄口服液、脑力静糖浆及脑力静胶囊。本 次拟收购标的股权对应的成交价格不高于 7,078.393 万元，并授权经理层具体 办理此次交易相关事宜。 本次公开摘牌结果尚存在不确定性。若成功摘牌，公司将持有精诚徽药 70%股权，实现对精诚徽药的实际控制权，并将其纳入公司合并报表范围。交易 完成后，公司及精诚徽药可能面临市场环境变化、管理整合以及行业与政策调 整等方面的风险。公司将密切关注相关动态，审慎评估并积极采取有效措施进 行风险防范与化解。 二、关于控股子公司江中饮片开展智慧代煎中心（二期）项目的议案 第十届董事会第八次会议决议公告 表决情况：9 票同意，0 票反对，0 ...

2025-050 证券代码：600750 证券简称：江中药业 公告编号： 江中药业股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 差异化分红送转： 否 一、通过分配方案的股东会届次和日期 本次利润分配方案经江中药业股份有限公司（以下简称"公司"）2025 年 9 月 8 日的2025年第一次临时股东会审议通过。 二、分配方案 1.发放年度：2025年半年度 每股分配比例 A 股每股现金红利0.5元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/10/10 | － | 2025/10/13 | 2025/10/13 | 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配以方案实施前的公司总股本 ...

Core Insights - On September 22, brokerages set target prices for listed companies, with notable increases for Gao Weida, SAIC Motor, and Haitian Flavoring, showing target price increases of 98.76%, 37.72%, and 27.18% respectively, across the software development, passenger vehicle, and seasoning industries [1][3] Group 1: Target Price Increases - Gao Weida received a target price of 51.50 yuan, reflecting a target price increase of 98.76% [3] - SAIC Motor's target price was set at 26.25 yuan, indicating a 37.72% increase [3] - Haitian Flavoring's target price reached 50.25 yuan, with a 27.18% increase [3] Group 2: Rating Adjustments - One company, Tebian Electric Apparatus, had its rating upgraded from "Hold" to "Strong Buy" by China Merchants Securities [4] - One company, Jiangling Motors, had its rating downgraded from "Buy" to "Hold" by Industrial Securities [5] Group 3: First Coverage - On September 22, brokerages initiated coverage on nine companies, including Jiangling Motors with a rating of "Hold" from Industrial Securities, and Ximai Food with a "Hold" rating from Shanxi Securities [6] - Gao Weida received a "Buy" rating from Dongwu Securities [6] - Other companies receiving coverage include Hengxin Life with a "Hold" rating and Xianglou New Materials with a "Hold" rating [6]

Investment Rating - The report maintains an "Accumulate" rating for Jiangzhong Pharmaceutical [6][12] Core Insights - The company is expected to achieve growth through both "internal" and "external" drivers, despite short-term pressure on OTC products due to changes in terminal demand [2][12] - The health consumer goods segment has shown positive growth through proactive adjustments, while the core OTC segment has faced challenges [2][12] Financial Summary - Total revenue for 2023 is projected at 4,553 million, with a slight decrease to 4,435 million in 2024, followed by a recovery to 4,525 million in 2025, and further growth to 5,004 million in 2026 and 5,548 million in 2027 [4][13] - Net profit attributable to the parent company is expected to rise from 719 million in 2023 to 788 million in 2024, reaching 841 million in 2025, and continuing to grow to 1,062 million by 2027 [4][13] - The earnings per share (EPS) is forecasted to increase from 1.13 in 2023 to 1.32 in 2025, and further to 1.67 by 2027 [4][13] Segment Performance - The OTC segment reported revenue of 1,550 million, a decline of 10.14% year-on-year, primarily due to changes in terminal demand [12] - Prescription drugs achieved revenue of 360 million, reflecting a year-on-year growth of 7.44%, indicating that the pressure from centralized procurement has largely been alleviated [12] - The health consumer goods segment generated revenue of 228 million, marking a year-on-year increase of 17.35%, driven by a focus on self-developed products and key categories [12] Cost Management - The company's gross margin for the first half of 2025 was 66.60%, a decrease of 2.44 percentage points year-on-year, while the net profit margin improved by 1.99 percentage points to 26.13% [12] - Sales, management, R&D, and financial expense ratios were effectively controlled, with sales expense ratio decreasing by 6.20 percentage points [12] Future Outlook - The company plans to enhance its OTC business through new product development and product introduction, while focusing on core categories in health consumer goods [12] - Active exploration of mergers and acquisitions is underway to consolidate industry resources and strengthen core product advantages [12]

Group 1 - The announcement pertains to the equity change of Jiangzhong Pharmaceutical Co., Ltd. by its controlling shareholder and its concerted parties, indicating a change that touches the 1% threshold [1][4]. - The controlling shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (referred to as "China Resources Jiangzhong"), plans to increase its shareholding in the company within 12 months starting from October 22, 2024, with a minimum investment of 60 million RMB and a maximum of 120 million RMB [4][5]. - As of the announcement date, China Resources Jiangzhong has cumulatively increased its shareholding by 2,784,350 shares, accounting for approximately 0.44% of the total share capital, with a total investment of 60,002,129.20 RMB [5][6]. Group 2 - The company completed the first registration of the second phase of its restricted stock incentive plan on June 6, 2025, which involved granting 6,128,000 shares, resulting in a change in total share capital from 628,868,022 shares to 634,996,022 shares [6]. - The shareholding percentage of China Resources Jiangzhong and its concerted parties decreased from 43.25% to 42.84% due to the stock incentive plan [6]. - The equity change does not result in a change of the controlling shareholder or actual controller of the company [6].

证券代码：600750 证券简称：江中药业 公告编号：2025-048 江中药业股份有限公司 关于控股股东及其一致行动人权益变动触及 1%刻度 的提示性公告 华润江中制药集团有限责任公司及其一致行动人保证向本公司提供的 信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息 一致。 重要内容提示： | 权益变动方向 | 比例增加 | 比例减少□ | | --- | --- | --- | | 权益变动前合计比例 | 42.84% | | | 权益变动后合计比例 | 43.13% | | | 本次变动是否违反已作出的承诺、意向、计划 | 是□ | 否 | | 是否触发强制要约收购义务 | 是□ | 否 | | | | | |  | 控股股东/实控人 | | | --- | --- | --- | --- | | 华润江中制药集团有 | □ | 控股股东/实控人的一致 | _91360000705507602N_ | | 限责任公司 | 行动人 | | □ 不适用 | | | □ | 其他直接持股股东 | | 3.一致行动人信息 注：变动 ...

Group 1 - The company held its shareholder meeting on September 8, 2025, at its conference room located at 788 Torch Avenue, High-tech Development Zone, Nanchang, Jiangxi Province [1] - The meeting was presided over by Chairman Liu Weiquan and utilized a combination of on-site and online voting methods, which complied with the Company Law and the Articles of Association [1] - All 9 current directors and 3 current supervisors attended the meeting, along with the board secretary and other senior executives [1] Group 2 - The first resolution regarding the 2025 semi-annual profit distribution plan was approved [2] - The second resolution concerning the reappointment of the auditing firm for 2025 was also approved [2] - Both resolutions required separate voting for minority investors [2] Group 3 - The legal firm Guohao Law Firm (Shanghai) provided witness services for the meeting, with lawyers Zhang Letian and Wu Haonan present [3] - The legal opinion confirmed that the meeting's convening and procedures complied with legal regulations and the Articles of Association, and that the qualifications of the conveners and attendees were valid [3]

致：江中药业股份有限公司 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于江中药业股份有限公司 2025 年第一次临时股东大会的法律意见书 江中药业股份有限公司（以下简称"公司"）2025 年第一次临时股东大会（以 下简称"本次股东大会"）现场会议定于 2025 年 9 月 8 日下午 14:50 在江西省南 昌市高新开发区火炬大街 788 号公司会议室召开，国浩律师（上海）事务所（以 下简称"本所"）接受公司的委托，指派本所律师出席会议，并依据《中华人民共 和国证券法》、《中华人民共和国公司法》和《江中药业股份有限公司章程》（以 下简称《公司章程》）出具本法律意见书。 本所律师已经按照有关法律、法规的规定对本次股东大会召集、召开程序是 否合法及是否符合《公司章程》、股东大会召集人资格的合法有效性、出席会议 人员资格的合法有效性和股东大会表决程序、表决结果等发表法律意见。法律意 见书中不存在虚假、严重误导性陈述及重大遗漏，否则愿意承担相应的法律责任。 本所律师是根据对事实的了解和对法律的理解发表法律意见。 本法律意见书依据国家有关法律、法规的规定而出具。 本所律师同意将本法律意见书作为公司本次 ...